No heart risk-or benefit-from diabetes drug Onglyza
Heart disease is the leading cause of death for people with diabetes. Diabetes drugs lower blood sugar, but that benefit must be weighed against possible harm to the heart—an evaluation now required by the FDA. Dr. Deepak L. Bhatt, editor in chief of the Harvard Heart Letter and professor of medicine at Harvard Medical School, co-led the most comprehensive study ever done of a diabetes drug's heart effects.
"Concerns have been raised about older diabetes drugs raising heart attack risk, so lack of such a hazard is a step forward in our understanding the risks and benefits of newer diabetes drugs," stated Dr. Bhatt.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
